# Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer

> **NCT00182806** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 38 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00182806
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-09
- **Final completion:** 2008-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2012-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00182806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00182806, "Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00182806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*